Search clinical trials for: tislelizumab disitamab-vedotin

Total 822 results

Tianjin Medical University Second Hospital

Recruiting

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Wuhan Union Hospital, China

Recruiting

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Breast Cancer | Neoadjuvant Therapy

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Colorectal Neoplasms

China
Tianjin Medical University Second Hospital

Recruiting

Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)

Neoadjuvant Immunotherapy

China
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
Qilu Hospital of Shandong University

Not yet recruiting

First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer (RCTS)

HER2-positive Gastric Cancer

China
RenJi Hospital
BeiGene; RemeGen Co., Ltd.

Recruiting

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

HER2 | Non-Muscle Invasive Bladder Cancer

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
RenJi Hospital

Recruiting

RC48-ADC in HER2-low Advanced Breast Cancer

Advanced Breast Cancer

China
West China Hospital

Not yet recruiting

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Breast Cancer

China
RemeGen Co., Ltd.

Not yet recruiting

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

High-risk Non-muscle Invasive Bladder Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer

Bladder Cancer

China
Qilu Hospital of Shandong University

Not yet recruiting

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Breast Cancer
Wuhan Union Hospital, China

Not yet recruiting

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Urothelial Carcinoma
Seagen Inc.

Recruiting

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Carcinoma, Squamous Cell of Head and Neck

United States, Australia, Canada
Zhejiang Cancer Hospital

Recruiting

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

HER2 Gene Mutation | Bile Duct Adenocarcinoma Non-Resectable

China
Zhongnan Hospital
Hubei Cancer Hospital; Sir Run Run Shaw Hospital; Huangshi Central Hospital,... and other collaborators

Active, not recruiting

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression (HCCSC-C03)

Colorectal Cancer | HER2

China
RemeGen Co., Ltd.

Recruiting

DV With HER2 Expression, Gene Amplification or Mutation Metastatic Castration-resistant Prostate Cancer

Castration-resistant Prostate Cancer

China
Peking University First Hospital
Peking University First Hospital Miyun Hospital

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery

Upper Urinary Tract Urothelial Carcinoma
Shanghai East Hospital

Recruiting

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Gastric Cancer | HER2-low-expressing Gastric Cancer

China
Xiangya Hospital of Central South University

Not yet recruiting

Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab

Gastric Cancer
RenJi Hospital

Recruiting

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Radiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug Conjugates

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer

Gastric Cancer
RemeGen Co., Ltd.

Not yet recruiting

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

China
The First Affiliated Hospital with Nanjing Medical...
First Affiliated Hospital of Wenzhou Medical University

Recruiting

A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

Breast Cancer

China
Xi'an International Medical Center Hospital

Not yet recruiting

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Shanxi Province Cancer Hospital

Recruiting

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
Shen Lin
RemeGen Co., Ltd.

Not yet recruiting

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Advanced Solid Tumor | Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma | HER2

China
The First Affiliated Hospital with Nanjing Medical...

Completed

A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Sun Yat-sen University

Not yet recruiting

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical...

Recruiting

RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer (RIGHT)

Biliary Carcinoma

China
Henan Cancer Hospital

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Gastric Cancer

China
Changhai Hospital

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nanfang Hospital of Southern Medical University; The Third Affiliated Hospital... and other collaborators

Not yet recruiting

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Bladder Cancer
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma | HER2-expressing

China
RemeGen Co., Ltd.

Recruiting

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Cancer

China
Shanghai Zhongshan Hospital

Not yet recruiting

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Colorectal Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

First-line Treatment | HER2-positive Metastatic Breast Cancer

China
RemeGen Co., Ltd.

Recruiting

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
RenJi Hospital

Recruiting

RC48-ADC in Breast Cancer

Breast Cancer

China
Guoxin Li

Not yet recruiting

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

Gastric Cancer
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma

United States, Canada, United Kingdom, Japan, Australia, Argentina, Chile, Israel
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Gastric Cancer

China
Seagen Inc.
RemeGen Co., Ltd.

Recruiting

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Stomach Neoplasms | Breast Neoplasms | Triple Negative Breast Neoplasms | Gastroesophageal Junction Adenocarcinoma | HER2 Positive Breast Neoplasms | HER2 Low Breast Neoplasms

United States
Shanghai Zhongshan Hospital
Takeda; BeiGene

Not yet recruiting

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

NK/T Cell Lymphoma Nos
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

HR Positive/HER2 Low Expression Metastatic Breast Cancer

China
RemeGen Co., Ltd.

Recruiting

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Solid Tumor

China
RemeGen Co., Ltd.

Recruiting

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication

3

Subscribe